Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KCLI$35.360.00(0.00%)Kansas City Life Declares Quarterly Dividend The Board of Directors of Kansas City Life Insurance Company declared a quarterly dividend of $0.18 per share on Oct. 26, 2026. The dividend will be...[6:09:00 PM ET]DSY$3.21-0.14(-4.18%)Big Tree Cloud Holdings Limited Announces Filing of Annual Report on Form 20-F for Fiscal Year 2026 Big Tree Cloud Holdings Limited ("Big Tree Cloud" or the "Company") (NASDAQ: DSY; DSYWW), a capital platform focusing on industrial integration and...[6:00:00 PM ET]GGB$4.65-0.45(-8.82%)Gerdau S.A. - Consolidated Information[6:00:00 PM ET]ULS$72.96-0.48(-0.65%)UL Solutions Opens Expanded Product Testing Facility in Vietnam[6:00:00 PM ET]POAS$1.45-0.48(-24.87%)Phaos Technology Holdings (Cayman) Limited Provides Required Going Concern Disclosure[6:00:00 PM ET]ARVLF$0.000.00(0.00%)Virgin Galactic Sets October 28 for Lead Delta Class Spaceship's Arrival at Spaceport America, Marking Start of Flight Test Preparations[5:58:00 PM ET]AWK$141.70-1.05(-0.74%)American Water Charitable Foundation Awards $10,000 Grant to Help Heartland Students Build Financial Skills The American Water Charitable Foundation, a philanthropic nonprofit organization established by American Water (NYSE: AWK), and Iowa American Water...[5:57:00 PM ET]HYOR$0.07+0.00(+0.13%)HyOrc Unveils European Expansion Strategy, Targets 150 TPD Waste-to-Methanol Facility in Portugal by 2028[5:53:08 PM ET]AMGN$444.00+4.74(+1.08%)AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS Amgen (NASDAQ: AMGN) today announced the appointment of David W. Gibbs to its Board of Directors, effective immediately. Gibbs will serve on the...[5:52:00 PM ET]PPTA$16.48+0.04(+0.24%)Perpetua Resources Awarded Up to $40 Million in U.S. Army Funding to Advance Domestic Tungsten Supply for American Defense Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources" or "Perpetua" or the "Company") today announced a new 36-month, $40 million ...[5:45:00 PM ET]VLRS$5.89+0.21(+3.70%)Volaris Reports Financial Results for the Third Quarter 2026: $1 Billion Revenue, up 32% YoY[5:30:00 PM ET]BLX$53.37-0.54(-1.00%)BLADEX ANNOUNCES QUARTERLY DIVIDEND PAYMENT FOR THIRD QUARTER 2026 Bladex, Inc. announced today its Board of Directors' approval of a quarterly cash dividend of US$0.6875 per share corresponding to the third quarter...[5:30:00 PM ET]

EYPT · NASDAQ

EyePoint Pharmaceuticals, Inc.

$0.36 -0.04 (-11.00%)

Company overview

EyePoint Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company offers ILUVIEN, an injectable sustained-release micro-insert for diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension for post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of a tyrosine kinase inhibitor for wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for chronic non-infectious uveitis affecting the posterior segment of the eye.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$30.2M
Employees
165
Headquarters
Watertown, MA
Website
eyepointpharma.com
CEO
Jay S. Duker
Listed
January 27, 2005
P/E
-0.10
Dividend yield
0.00%

Company financials

Revenue
$7.6M
Gross profit
$5.8M
Operating income
-$282M
EBITDA
-$278M
Net income
-$272M
EPS
-$3.50
Total assets
$288M
Total debt
$20.2M
Gross margin
76.51%
Net margin
-3,566.63%
Earnings yield
-972.22%

Revenue segmentation

By product (FY 2024)
By region (FY 2024)

Showing FY 2024

Price chart

-0.243.968.1512.3516.54
EYPT 1D NASDAQ O0.42H0.43L0.40C0.40-0.02 (-5.51%)Vol13.33M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
EYPTEyePoint Pharmaceuticals, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT ACCESS Newswire
EYPTEyePoint Pharmaceuticals, Inc. Legal EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky GlobeNewswire
EYPTEyePoint Pharmaceuticals, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against EyePoint, Inc. (EYPT) And Encourages Stockholders to Reach Out ACCESS Newswire
EYPTEyePoint Pharmaceuticals, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT ACCESS Newswire
EYPTEyePoint Pharmaceuticals, Inc. Legal Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT) GlobeNewswire
EYPTEyePoint Pharmaceuticals, Inc. Legal EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) ACCESS Newswire
EYPTEyePoint Pharmaceuticals, Inc. Legal EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals Shares of EyePoint Pharmaceuticals (NASDAQ: EYPT) have lost roughly 80% of their value after the Company's Phase . PR Newswire
EYPTEyePoint Pharmaceuticals, Inc. Legal EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT) EyePoint Pharmaceuticals (NASDAQ: EYPT) saw nearly 80% of its market value erased after the mar. PR Newswire
EYPTEyePoint Pharmaceuticals, Inc. Stock news EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus Benzinga
EYPTEyePoint Pharmaceuticals, Inc. Stock news EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript Seeking Alpha
EYPTEyePoint Pharmaceuticals, Inc. Press release EyePoint Announces Strategic Prioritization GlobeNewswire
EYPTEyePoint Pharmaceuticals, Inc. Press release EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD GlobeNewswire
EYPTEyePoint Pharmaceuticals, Inc. Stock news Comparing Eyepoint Pharmaceuticals (NASDAQ:EYPT) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP) Defense World
EYPTEyePoint Pharmaceuticals, Inc. Stock news Here's Why You Should Add EYPT Stock to Your Portfolio Now Zacks Investment Research
EYPTEyePoint Pharmaceuticals, Inc. Press release EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewsWire
EYPTEyePoint Pharmaceuticals, Inc. Stock news Bristol Myers Squibb (NYSE:BMY) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) Financial Analysis Defense World
EYPTEyePoint Pharmaceuticals, Inc. Stock news EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
EYPTEyePoint Pharmaceuticals, Inc. Legal EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP GlobeNewsWire
EYPTEyePoint Pharmaceuticals, Inc. Stock news EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
EYPTEyePoint Pharmaceuticals, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT GlobeNewsWire
See more
FAQ

Questions about EyePoint Pharmaceuticals, Inc.

What does EyePoint Pharmaceuticals, Inc. do?
EyePoint Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company offers ILUVIEN, an injectable sustained-release micro-insert for diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension for post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of a tyrosine kinase inhibitor for wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for chronic non-infectious uveitis affecting the posterior segment of the eye.
What is EYPT's market cap?
EyePoint Pharmaceuticals, Inc. (EYPT) is a listed stock with a live quote. The latest market cap on this page is $30.2M.
Where is EyePoint Pharmaceuticals, Inc. headquartered?
EyePoint Pharmaceuticals, Inc. is headquartered in Watertown, MA.
How do I get EYPT news from the API?
Call GET /v1/news?tickers=EYPT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does EYPT news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for EYPT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the EYPT price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs